Current Pipeline of CDK 7 Inhibitors in Clinical Development
As more drugs move through the pipeline and clinical data accumulates, the market for CDK 7 inhibitors is expected to expand rapidly. The ongoing focus on precision medicine and the identification of biomarkers that predict response to CDK 7 inhibitors will further drive the development of
